- Home
- / Cytek Biosciences
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Cytek Biosciences financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$4.8
2024-10-29
Market Capitalization
$632.5 M
2024-10-29
Revenue
$201.5 M
FY, 2025
CreditSafe Score
?
Score changed on Jun 08, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 128.0M | 164.0M | 193.0M | 200.5M | 201.5M |
| Cost of goods sold | 48.8M | 63.1M | 83.6M | 89.3M | 97.0M |
| Gross profit | 79.1M | 101.0M | 109.4M | 111.1M | 104.5M |
| Gross profit margin, % | 61.6% | 55.4% | 51.8% | ||
| General and administrative expense | 20.8M | 34.7M | 44.0M | 43.1M | 58.9M |
| Operating expense total | 70.0M | 102.8M | 137.3M | 131.6M | 144.8M |
| EBIT | 9.2M | (1.8M) | (27.8M) | (20.5M) | (40.4M) |
| EBIT margin, % | -1.1% | -10.2% | -20.0% | ||
| Interest income | 49.0K | 4.6M | 6.4M | 5.1M | 2.2M |
| Interest expense | 2.1M | ||||
| Pre tax profit | 5.9M | 1.3M | (15.7M) | (5.7M) | (29.8M) |
| Income tax expense | 2.9M | (1.2M) | (3.6M) | 320.0K | 36.7M |
| Net Income | 3.0M | 2.5M | (12.1M) | (6.0M) | (66.5M) |
| EPS | 0.0 |